By Mill Chart
Last update: Jul 1, 2025
GENMAB A/S (NASDAQ:GMAB) was identified by our Peter Lynch-inspired stock screener as a company with solid growth prospects and a reasonable valuation. The Danish biotechnology firm specializes in developing antibody-based cancer treatments and has a track record of profitability, strong financial health, and attractive valuation metrics.
Our fundamental analysis assigns GMAB a rating of 6 out of 10, highlighting:
For a deeper look, review the full fundamental report on GMAB.
Our Peter Lynch Strategy screener lists more stocks meeting these criteria and is updated daily.
This is not investing advice. Always conduct your own research before making investment decisions.
20.74
+0.08 (+0.39%)
Find more stocks in the Stock Screener
GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy.